What Is Sovateltide? Definition and What Research Reports

Definition

Sovateltide is a synthetic peptide that acts as a selective agonist at the endothelin B (ETB) receptor. Structurally it is a modified, truncated analogue of endothelin-1, the endogenous 21-amino-acid vasoactive peptide produced by vascular endothelium; the modifications were designed to preserve activity at the ETB receptor while avoiding activity at the endothelin A (ETA) receptor, and a 2022 review described sovateltide's pharmacology specifically in terms of ETB receptor agonism and its application to neurological disorders (PMID 35328566). In the literature the compound appears under several names — sovateltide is the international non-proprietary name, while the development codes IRL-1620 and PMZ-1620 are used interchangeably in older and preclinical publications.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Nothing here describes how any substance should be used.

What Class of Molecule Is It?

Sovateltide belongs to the class of peptide receptor agonists. Unlike small-molecule drugs, its activity derives from a short chain of amino acids that mimics part of a naturally occurring signalling peptide. Endothelin-1 signals through two G-protein-coupled receptors, ETA and ETB, which have broadly opposing roles in vascular tone; sovateltide was developed to engage the ETB arm of that system selectively, and the 2022 review framed this selectivity as the mechanistic rationale behind its investigation in brain injury (PMID 35328566).

Names and identifiers used in the literature

How the Term Is Used in Peptide Research

In peptide literature, "sovateltide" is generally used in one of three ways. First, as the name of a specific investigational and, in at least one jurisdiction, approved drug product for acute cerebral ischaemic stroke — a 2023 Drugs "First Approval" profile summarised its development and its first regulatory approval in that indication (PMID 37486545). Second, as a pharmacological tool compound: researchers have used IRL-1620 in animal models to probe what happens when the ETB receptor is selectively stimulated in the central nervous system. Third, as an example in reviews of regenerative or neurorepair strategies, where the interest is less in vasodilation and more in downstream effects on progenitor cells and mitochondria.

Because the compound is a prescription pharmaceutical rather than a research chemical sold for general use, most of the literature is clinical-trial and animal-model literature rather than exploratory human pharmacology.

What the Published Literature Reports

Animal studies

Several rodent studies examined what sovateltide did after experimentally induced brain or spinal cord injury. In a 2020 study in adult rats following cerebral ischaemia, researchers reported that sovateltide was associated with activation of neuronal differentiation and with prevention of mitochondrial dysfunction in the injured brain (PMID 32728189). A companion 2020 report described effects on neuronal progenitor cells and reduced cerebral tissue damage after ischaemic stroke in an animal model (PMID 32574518).

The compound was also examined outside the classic adult stroke model. A 2022 study in a neonatal rat model of hypoxic-ischaemic encephalopathy reported a neuroprotective effect of sovateltide (IRL 1620, PMZ 1620) in that setting (PMID 34826534). In a separate 2024 rat model of spinal cord injury, the study reported improved motor function and reduced hyperalgesia in treated animals (PMID 38443708). These findings are animal findings and were not, in those papers, extended to humans.

Clinical trials

The human evidence base centres on acute cerebral ischaemic stroke. A 2021 multicentre randomised controlled trial examined the safety and efficacy of sovateltide (IRL-1620) added to standard care in patients with acute cerebral ischaemic stroke, and the researchers reported that it was well tolerated and that neurological outcome measures at follow-up favoured the sovateltide group (PMID 33428177).

A larger randomised, double-blind, placebo-controlled, multicentre phase III trial published in 2024 evaluated intravenous sovateltide at 0.3 µg/kg per dose given as three doses on each of days 1, 3 and 6 alongside standard treatment in acute cerebral ischaemic stroke (PMID 39542995). That phase III report described outcomes assessed with standard stroke scales — the modified Rankin Scale, the National Institutes of Health Stroke Scale and the Barthel Index — at 90 days, with the sovateltide arm showing greater improvement than placebo on those measures (PMID 39542995).

Beyond randomised trials, a 2026 prospective observational study examined real-world functional outcomes when sovateltide was used as an adjunct to standard therapy in acute ischaemic stroke and reported outcomes in routine clinical practice rather than in a controlled trial setting (PMID 41731809). Observational designs of this kind cannot separate drug effect from patient selection.

Proposed but unestablished directions

Reviews have speculated about indications beyond acute stroke. A 2026 review discussed sovateltide in the context of the heart–brain axis in Alzheimer's disease and framed it as a proposed multi-target therapeutic approach (PMID 41910699). Such review articles describe hypotheses and mechanistic reasoning; they are not clinical outcome evidence, and the reader should treat them as agenda-setting rather than conclusive.

Safety and Adverse Events: What Studies Report

Safety data for sovateltide come principally from its stroke trials. The 2021 multicentre randomised controlled trial was designed to evaluate safety as well as efficacy, and the researchers reported that sovateltide was safe and well tolerated in the studied population (PMID 33428177). The 2024 phase III trial likewise reported on safety alongside efficacy in patients with acute cerebral ischaemic stroke receiving the drug in addition to standard care (PMID 39542995). The 2023 regulatory profile summarised the approval that followed this development programme (PMID 37486545).

Important context: safety observed in hospitalised stroke patients receiving short, supervised intravenous courses does not generalise to other populations, other routes, other durations or other indications. No verified publication listed here characterised long-term exposure or use outside the acute neurological settings described above.

Limits of the Evidence

• Narrow indication base. Nearly all human data concern acute cerebral ischaemic stroke within a defined treatment window (PMID 39542995).
• Animal-to-human gap. The progenitor-cell, mitochondrial and spinal-cord findings were obtained in rodents (PMID 32728189, PMID 38443708).
• Geographic limits on approval. The 2023 first-approval profile documented an initial regulatory approval rather than worldwide authorisation (PMID 37486545).
• Hospital context. Published administration occurred intravenously in acute-care settings alongside standard stroke therapy (PMID 33428177).

Related Terms

Readers encountering sovateltide will often also encounter endothelin-1 (the parent signalling peptide), ETA and ETB receptors (its two receptor subtypes), and neurorepair or neuronal progenitor terminology, all of which appear in the mechanistic review literature on this compound (PMID 35328566).

References

• Sovateltide: First Approval (Drugs, 2023)
• Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial (Drugs, 2024)
• Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders (International Journal of Molecular Sciences, 2022)
• Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury (Neurocritical Care, 2024)
• Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke (Scientific Reports, 2020)
• Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke (Canadian Journal of Physiology and Pharmacology, 2020)
• Neuroprotective Effect of Sovateltide (IRL 1620, PMZ 1620) in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy (Neuroscience, 2022)
• Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke (CNS Drugs, 2021)
• Sovateltide at the heart-brain axis crosstalk in Alzheimer's disease: a promising multi-target and cutting-edge therapeutic approach (Inflammopharmacology, 2026)
• Real-world functional outcomes of sovateltide as an adjunct to standard therapy in acute ischemic stroke: A prospective observational study (Medicine, 2026)